RBC Capital analyst Shagun Singh raised the firm’s price target on Stryker to $345 from $315 and keeps an Outperform rating on the shares as part of a broader research note previewing MedTech for 2024. The company’s organic growth was driven by underlying solid business momentum and “super cycle” of new products ramping up and hitting the market in 2023, the analyst tells investors in a research note. 2024 should be another strong year for Stryker as supply improves, while the new products/new indications, backlog pull-through, and strong capital demand should positively impact the MedSurg & Neurotech and Orthopedics & Spine sides, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYK:
- Stryker sees 1st case using Blueprint MR system in Europe in February
- Stryker announces 2023 sales surpassed $20B
- Stryker announces 2023 sales surpassed $20 billion
- Stryker to announce financial results for its fourth quarter and full year 2023
- 5 Top MedTech Stocks for 2024, According to Analysts from Baird
